Latest Commercialisation News

Urbanise.com Limited reported 14.3% revenue growth to $15 million in FY2026, significantly narrowing its net loss to $0.9 million while advancing a NAB partnership pilot and launching AI features.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

Calix Limited posted a 16% revenue increase to $39.2 million in FY26 driven by strong growth in its Magnesia business, while reporting a substantial net loss of $51 million largely due to a one-off impairment. The company advanced key industrial decarbonisation projects and strengthened strategic partnerships, focusing on capital-light commercialisation.

BCAL Diagnostics has increased its shareholding in Genetic Signatures to nearly a fifth, aiming to leverage infectious disease technology to complement its cancer detection portfolio.

Hiremii Limited posted an 8.6% revenue increase to $32.4 million and halved its net loss in FY26, reaching adjusted EBITDA breakeven as it prepares to rebrand as AQYR Limited.

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

Advanced Braking Technology Ltd (ASX: ABV) posted a 22.7% revenue increase to $23.48 million and a 16.6% rise in net profit after tax to $2.075 million for FY26, driven by international expansion and advances in autonomous braking technology.

Nine Entertainment Co. Holdings Limited posted a $511 million statutory net profit for FY26, driven by significant portfolio restructuring and growth in digital and outdoor advertising, while advancing AI licensing partnerships.

Metallium has resolved a key permitting constraint at its Texas Gator Point campus, enabling chlorinated Flash Joule Heating testing to resume ahead of a major September campaign. The company also marks first revenue from its MXene development program and strengthens engineering leadership.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.